GLP-1 agonists are being used in combination with basal insulin (Dungan & DeSantis, 2016), although this is not an FDA-approved indication (see rxlist.com) they should not be used as a substitute for basal insulin, as this has been found to result in a decline in glycemic control)(Dungan & DeSantis, 2016) Clinical trials indicate it can reduce HbA1c by ~0.8% Undergoes renal clearance, with dosage reduction needed if creatinine clearance falls to 25 mL/min, while European guidelines recommend a lower eGFR limit of 20 ml/min (Thomas et al, 2023)
Include a serving of protein at each meal
Key advantage: Works even when Viagra/Cialis fail No interaction with alcohol or food Effective in neurogenic, psychogenic, and post-surgical ED Indications Erectile dysfunction (especially PDE-5 non-responders) Low libido (male & female) Performance anxietyassociated ED Adjunct to PDE-5 inhibitors Post-prostate or vascular compromise patients Administration Route : Subcutaneous injection Site : Abdomen or thigh Needle : 31G insulin syringe Timing : On-demand Dosing guidelines Start Low, Titrate Up Men Starting dose: 0.5 mg SQ Typical effective dose: 1.0 mg SQ Max dose: 1.52.0 mg SQ Frequency: No more than 1 dose per 24 hours, 23x per week max Women Starting dose: 0.250.5 mg SQ Typical dose: 0.51.0 mg SQ Onset & duration Onset: 3090 minutes Peak effect: ~24 hours Duration: 612 hours (sometimes longer) Important counseling point:PT-141 increases desire first , erection may follow
Q2: Have GLP-1 drugs been linked to serious conditions like pancreatitis or thyroid cancer
While its primary focus was device regulatory scope (FDA found the Exer Scan was marketed beyond the limits of its 510(k) exemption), the letter also enumerated major quality system deficiencies lack of design control procedures, no CAPA system, no complaint-handling SOPs, no auditing processes, etc